Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Parkinson's Progression Markers Initiative

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P

Original languageEnglish (US)
Pages (from-to)919-927
Number of pages9
JournalMovement Disorders
Volume30
Issue number7
DOIs
StatePublished - Jun 1 2015

Fingerprint

Parkinson Disease
Disruptive, Impulse Control, and Conduct Disorders
Apathy
Aptitude
Psychotic Disorders
Cognition
Anxiety
Quality of Life
Demography
Depression
Cognitive Dysfunction

Keywords

  • Anxiety
  • Apathy
  • Cognition
  • Depression
  • Impulse control disorder
  • Parkinson's disease
  • Psychosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. / Parkinson's Progression Markers Initiative.

In: Movement Disorders, Vol. 30, No. 7, 01.06.2015, p. 919-927.

Research output: Contribution to journalArticle

Parkinson's Progression Markers Initiative. / Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. In: Movement Disorders. 2015 ; Vol. 30, No. 7. pp. 919-927.
@article{d5eb365e6014493e879d27270b7fd9fd,
title = "Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease",
abstract = "This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9{\%} met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P",
keywords = "Anxiety, Apathy, Cognition, Depression, Impulse control disorder, Parkinson's disease, Psychosis",
author = "{Parkinson's Progression Markers Initiative} and Daniel Weintraub and Tanya Simuni and Chelsea Caspell-Garcia and Christopher Coffey and Shirley Lasch and Andrew Siderowf and Dag Aarsland and Paolo Barone and David Burn and Chahine, {Lama M.} and Jamie Eberling and Espay, {Alberto J.} and Foster, {Eric D.} and Leverenz, {James B.} and Irene Litvan and Irene Richard and Troyer, {Matthew D.} and Hawkins, {Keith A.} and Kenneth Marek and Danna Jennings and Caroline Tanner and Karl Kieburtz and Werner Poewe and Brit Mollenhauer and Tatiana Foroud and Douglas Galasko and Todd Sherer and Sohini Chowdhury and Mark Frasier and Catherine Kopil and Vanessa Arnedo and Alice Rudolph and John Seibyl and Susan Mendick and Norbert Schuff and Chelsea Caspell and Liz Uribe and Eric Foster and Katherine Gloer and Jon Yankey and Arthur Toga and Dorit Berlin and Paola Casalin and Giulia Malferrari and John Trojanowski and Les Shaw and David Russell and Stewart Factor and Penelope Hogarth and David Standaert",
year = "2015",
month = "6",
day = "1",
doi = "10.1002/mds.26170",
language = "English (US)",
volume = "30",
pages = "919--927",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

AU - Parkinson's Progression Markers Initiative

AU - Weintraub, Daniel

AU - Simuni, Tanya

AU - Caspell-Garcia, Chelsea

AU - Coffey, Christopher

AU - Lasch, Shirley

AU - Siderowf, Andrew

AU - Aarsland, Dag

AU - Barone, Paolo

AU - Burn, David

AU - Chahine, Lama M.

AU - Eberling, Jamie

AU - Espay, Alberto J.

AU - Foster, Eric D.

AU - Leverenz, James B.

AU - Litvan, Irene

AU - Richard, Irene

AU - Troyer, Matthew D.

AU - Hawkins, Keith A.

AU - Marek, Kenneth

AU - Jennings, Danna

AU - Tanner, Caroline

AU - Kieburtz, Karl

AU - Poewe, Werner

AU - Mollenhauer, Brit

AU - Foroud, Tatiana

AU - Galasko, Douglas

AU - Sherer, Todd

AU - Chowdhury, Sohini

AU - Frasier, Mark

AU - Kopil, Catherine

AU - Arnedo, Vanessa

AU - Rudolph, Alice

AU - Seibyl, John

AU - Mendick, Susan

AU - Schuff, Norbert

AU - Caspell, Chelsea

AU - Uribe, Liz

AU - Foster, Eric

AU - Gloer, Katherine

AU - Yankey, Jon

AU - Toga, Arthur

AU - Berlin, Dorit

AU - Casalin, Paola

AU - Malferrari, Giulia

AU - Trojanowski, John

AU - Shaw, Les

AU - Russell, David

AU - Factor, Stewart

AU - Hogarth, Penelope

AU - Standaert, David

PY - 2015/6/1

Y1 - 2015/6/1

N2 - This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P

AB - This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P

KW - Anxiety

KW - Apathy

KW - Cognition

KW - Depression

KW - Impulse control disorder

KW - Parkinson's disease

KW - Psychosis

UR - http://www.scopus.com/inward/record.url?scp=84931955787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931955787&partnerID=8YFLogxK

U2 - 10.1002/mds.26170

DO - 10.1002/mds.26170

M3 - Article

C2 - 25737166

AN - SCOPUS:84931955787

VL - 30

SP - 919

EP - 927

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -